Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Crispr Therapeutics AG (NASDAQ:CRSP) on Wednesday, setting a price target of $171, which is approximately 66.68% above the present share price of $102.59.
Livshits expects Crispr Therapeutics AG to post earnings per share (EPS) of $10.01 for the fourth quarter of 2021.
The current consensus among 9 TipRanks analysts is for a Strong Buy rating of shares in Crispr Therapeutics AG, with an average price target of $155.5.
The analysts price targets range from a high of $185 to a low of $101.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $900.7 million and a net profit of $762.62 million. The company's market cap is $7.82 billion.
According to TipRanks.com, Chardan Capital analyst Geulah Livshits is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 69.3% and a 59.13% success rate.
CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.